Company intelligence / Profile preview

Ceptaris Therapeutics

Malvern, Pennsylvania, United Statesbiospace.com ↗

Ownership: Private
Development stage: Other

Overview

Yaupon Therapeutics developed a proprietary topical gel formulation of mechlorethamine hydrochloride for early-stage mycosis fungoides (a type of CTCL). The product reached NDA submission and FDA review by 2011–2012. The company also advanced lobeline, derived from Lobelia inflata, into clinical trials targeting methamphetamine addiction relapse prevention[3][5]. In January 2012, the company changed its name to Ceptaris Therapeutics and was later acquired.

Therapeutic areas: PsychiatryOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ceptaris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceptaris Therapeutics.

Explore the full profile